Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $0 and sold $6.67M worth of Day One Biopharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $34.92M and sold $17.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.
2024-11-18 | Sale | HEAD OF R&D | 2,206 0.0022% | $13.21 | $29,142 | +2.61% | ||
2024-11-18 | Sale | COO, CFO AND SECRETARY | 2,602 0.0026% | $13.21 | $34,373 | +2.61% | ||
2024-11-18 | Sale | CHIEF EXECUTIVE OFFICER | 10,554 0.0106% | $13.21 | $139,420 | +2.61% | ||
2024-11-18 | Sale | GENERAL COUNSEL | 3,165 0.0032% | $13.21 | $41,810 | +2.61% | ||
2024-11-11 | Sale | HEAD OF R&D | 10,000 0.01% | $16.10 | $160,994 | -13.49% | ||
2024-11-08 | Sale | HEAD OF R&D | 18,255 0.0176% | $16.17 | $295,229 | -16.29% | ||
2024-11-07 | Sale | HEAD OF R&D | 11,245 0.0113% | $16.03 | $180,287 | -12.94% | ||
2024-10-31 | Sale | HEAD OF R&D | 500 0.0006% | $16.02 | $8,010 | -5.37% | ||
2024-09-10 | Sale | HEAD OF R&D | 30,000 0.0339% | $14.22 | $426,675 | -1.67% | ||
2024-08-16 | Sale | HEAD OF R&D | 2,232 0.0027% | $14.00 | $31,246 | 0.00% | ||
2024-08-16 | Sale | COO, CFO AND SECRETARY | 2,633 0.0031% | $14.00 | $36,860 | 0.00% | ||
2024-08-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,681 0.0127% | $14.00 | $149,524 | 0.00% | ||
2024-08-16 | Sale | GENERAL COUNSEL | 3,202 0.0038% | $14.00 | $44,825 | 0.00% | ||
2024-07-16 | Sale | HEAD OF R&D | 20,000 0.0273% | $16.01 | $320,226 | -11.99% | ||
2024-06-21 | Sale | director | 10,000 0.012% | $13.19 | $131,877 | +2.96% | ||
2024-06-10 | Sale | HEAD OF R&D | 30,000 0.0347% | $12.62 | $378,588 | +11.81% | ||
2024-05-16 | Sale | HEAD OF R&D | 2,267 0.0026% | $16.08 | $36,450 | -13.23% | ||
2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 7,873 0.009% | $16.08 | $126,588 | -13.23% | ||
2024-05-16 | Sale | COO, CFO AND SECRETARY | 2,675 0.0031% | $16.08 | $43,011 | -13.23% | ||
2024-05-16 | Sale | GENERAL COUNSEL | 3,253 0.0037% | $16.08 | $52,304 | -13.23% |
Blackman Samuel C. | HEAD OF R&D | 1064015 1.0551% | $13.62 | 0 | 35 | |
York Charles N II | COO, CFO AND SECRETARY | 240133 0.2381% | $13.62 | 0 | 24 | |
Bender Jeremy | CHIEF EXECUTIVE OFFICER | 108377 0.1075% | $13.62 | 0 | 24 | |
Ramasastry Saira | director | 40485 0.0401% | $13.62 | 0 | 1 | |
Dubow Adam | GENERAL COUNSEL | 32162 0.0319% | $13.62 | 0 | 5 | |
AI Day1 LLC | 10 percent owner | 12929322 12.8209% | $13.62 | 8 | 0 | +13.88% |
Blavatnik Len | 10684638 10.595% | $13.62 | 1 | 0 | +23.65% | |
Canaan XI L.P. | 10 percent owner | 8464301 8.3933% | $13.62 | 1 | 7 | <0.0001% |
TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 6120124 6.0688% | $13.62 | 0 | 4 | |
Atlas Venture Associates Opportunity I, LLC | 766667 0.7602% | $13.62 | 1 | 0 | +23.65% | |
Gladstone Michael | 766667 0.7602% | $13.62 | 1 | 0 | +23.65% | |
Atlas Venture Fund XI, L.P. | 10 percent owner | 741396 0.7352% | $13.62 | 2 | 0 | <0.0001% |
Grant Julie Papanek | director | 330000 0.3272% | $13.62 | 1 | 24 | <0.0001% |
Josey John A. | director | 72292 0.0717% | $13.62 | 1 | 0 | <0.0001% |
Becker Daniel J. | director | 5000 0.005% | $13.62 | 1 | 0 | <0.0001% |
RA Capital Management, L.P. | $129.02M | 8.94 | 7.81M | 0% | +$0 | 0.13 | |
Atlas Venture Life Science Advisors Llc | $106.23M | 7.36 | 6.43M | -15.48% | -$19.46M | 9.86 | |
BlackRock | $83.12M | 5.76 | 5.03M | -1.85% | -$1.56M | <0.01 | |
The Vanguard Group | $78.87M | 5.46 | 4.77M | +0.1% | +$78,255.24 | <0.01 | |
Fidelity Investments | $72.76M | 5.04 | 4.4M | +10.99% | +$7.21M | 0.01 | |
Franklin Templeton Investments | $62.89M | 4.36 | 3.81M | -10.15% | -$7.1M | 0.02 | |
State Street | $47.82M | 3.31 | 2.89M | -14.36% | -$8.02M | <0.01 | |
Viking Global Investors | $42.27M | 2.93 | 2.56M | 0% | +$0 | 0.02 | |
T. Rowe Price | $37.99M | 2.63 | 2.3M | -0.73% | -$280,846.64 | 0.01 | |
Braidwell Lp | $35.91M | 2.49 | 2.17M | -48.44% | -$33.73M | 2.04 | |
Goldman Sachs | $35.31M | 2.45 | 2.14M | +0.88% | +$307,965.84 | 0.01 | |
Janus Henderson | $33.57M | 2.33 | 2.03M | +19.83% | +$5.56M | 0.02 | |
Deerfield Management | $29.16M | 2.02 | 1.77M | +0.23% | +$68,293.68 | 0.07 | |
TimesSquare Capital Management LLC | $27.01M | 1.87 | 1.64M | -1.86% | -$510,806.05 | 0.4 | |
Geode Capital Management | $22.75M | 1.58 | 1.38M | +2.09% | +$464,972.27 | <0.01 | |
Maverick Capital Ltd | $20.76M | 1.44 | 1.26M | New | +$20.76M | 0.4 | |
Boxer Capital, LLC | $19.66M | 1.36 | 1.19M | 0% | +$0 | 0.4 | |
Polar Capital | $19.58M | 1.36 | 1.19M | -14.44% | -$3.3M | 0.11 | |
Dimensional Fund Advisors | $16.22M | 1.12 | 981,572 | +26.18% | +$3.36M | <0.01 | |
Driehaus Capital Management LLC | $11.88M | 0.82 | 719,011 | +48.79% | +$3.89M | 0.12 | |
Parkman Healthcare Partners Llc | $11.43M | 0.79 | 691,812 | +10.56% | +$1.09M | 1.42 | |
DAFNA Capital Management, LLC | $11.01M | 0.76 | 666,463 | -2.91% | -$330,400.01 | 0.27 | |
Northern Trust | $9.22M | 0.64 | 558,145 | -3.23% | -$307,387.63 | <0.01 | |
Sphera Fund | $8.14M | 0.56 | 492,627 | -3.97% | -$336,561.96 | 0.05 | |
Charles Schwab | $7.56M | 0.52 | 457,652 | +1.04% | +$77,941.36 | <0.01 | |
Nicholas Investment Partners, L.P. | $5.98M | 0.41 | 361,767 | +19.27% | +$965,577.51 | 0.68 | |
PFM Health Sciences | $5.87M | 0.41 | 355,251 | -72.75% | -$15.67M | 0.16 | |
Candriam S C A | $4.79M | 0.33 | 290,014 | 0% | +$0 | 0.03 | |
Woodline Partners LP | $4.5M | 0.31 | 272,538 | 0% | +$0 | 0.04 | |
Wellington Management Company | $4.5M | 0.31 | 272,117 | +30.22% | +$1.04M | <0.01 | |
Schonfeld Group | $3.93M | 0.27 | 237,748 | +32.87% | +$971,607.04 | 0.02 | |
Morgan Stanley | $3.84M | 0.27 | 232,550 | -30.47% | -$1.68M | <0.0001 | |
D. E. Shaw & Co. | $3.7M | 0.26 | 224,219 | +14.7% | +$474,619.61 | <0.01 | |
BNY Mellon | $3.56M | 0.25 | 215,383 | -8.03% | -$310,823.87 | <0.01 | |
Samsara Biocapital Llc | $3.24M | 0.23 | 196,425 | 0% | +$0 | 0.51 | |
Rafferty Asset Management Llc | $3.19M | 0.22 | 193,224 | -18.25% | -$712,391.85 | 0.01 | |
Deutsche Bank | $2.94M | 0.2 | 178,174 | +0.57% | +$16,817.36 | <0.01 | |
Nuveen | $2.9M | 0.2 | 175,775 | 0% | +$0 | <0.01 | |
Simplify Asset Management Inc | $2.89M | 0.2 | 175,018 | 0% | +$0 | 0.28 | |
Citigroup | $2.83M | 0.2 | 171,050 | +71.18% | +$1.17M | <0.01 | |
Prudential Financial | $2.8M | 0.19 | 169,522 | New | +$2.8M | <0.01 | |
Laurion Capital Management LP | $2.73M | 0.19 | 164,983 | 0% | +$0 | 0.02 | |
UBS | $2.71M | 0.19 | 164,018 | +29.52% | +$617,484.48 | <0.01 | |
Adage Capital Partners Gp L L C | $2.63M | 0.18 | 159,000 | +6% | +$148,680.00 | 0.01 | |
Marshall Wace | $2.22M | 0.15 | 134,171 | +13.81% | +$268,896.05 | <0.01 | |
Bank of America | $2.11M | 0.15 | 127,589 | -20.2% | -$533,513.33 | <0.0001 | |
Macquarie Group | $1.82M | 0.13 | 110,000 | 0% | +$0 | <0.01 | |
Hudson Bay Capital Management LP | $1.82M | 0.13 | 110,000 | +37.5% | +$495,600.00 | 0.01 | |
ExodusPoint Capital Management, LP | $1.61M | 0.11 | 97,621 | +138.66% | +$937,156.29 | 0.02 | |
Swiss National Bank | $1.58M | 0.11 | 95,400 | 0% | +$0 | <0.01 |